Exudative AMD subtypes and eligibility for treatment with ranibizumab
| Data(s) |
01/07/2010
|
|---|---|
| Resumo |
Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials. |
| Identificador |
http://dx.doi.org/10.1038/eye.2009.301 http://www.scopus.com/inward/record.url?scp=77954726273&partnerID=8YFLogxK |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
George , S , Cooke , C & Chakravarthy , U 2010 , ' Exudative AMD subtypes and eligibility for treatment with ranibizumab ' Eye , vol 24 , no. 7 , pp. 1247-1251 . DOI: 10.1038/eye.2009.301 |
| Palavras-Chave | #/dk/atira/pure/subjectarea/asjc/2700/2731 #Ophthalmology |
| Tipo |
article |
